{
    "clinical_study": {
        "@rank": "144457", 
        "arm_group": {
            "arm_group_label": "Cancer Group", 
            "description": "Not Applicable"
        }, 
        "brief_summary": {
            "textblock": "This study aims to analyze the incidence of expression of MAGE-A3, MAGE-C2, NY-ESO-1,\n      LAGE-1, WT1 and PRAME tumor antigens in cancer tissue from patients with pathologically\n      demonstrated bladder cancer."
        }, 
        "brief_title": "Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer", 
        "completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "condition": "Pathologically Demonstrated Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "There will be no procedure(s) or treatment(s) carried out on patients. All data and samples\n      will be taken from those already stored at the investigation sites.  Clinical data collected\n      will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system)\n      [TNM stage], and histopathologic description only. Strict anonymity of patient data will be\n      maintained.\n\n      This retrospective study is based upon the analysis of archived formalin-fixed\n      paraffin-embedded tissue samples and patient-related data already available at the\n      investigational site."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For inclusion of a tissue sample, all of the following criteria must be met:\n\n          -  The patient had pathologically proven bladder cancer (any stage).\n\n          -  All the data required are available from patient's records.\n\n        There are no restrictions regarding operative technique (cystectomy or cystoscopy).\n\n        -  Many patients may no longer be alive, or no longer be in contact with the investigation\n        sites. Thus, patients will not be required to give their informed consent before inclusion\n        in the study.\n\n        Exclusion Criteria:\n\n          -  Not applicable."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Previously collected samples and data of patients with pathologically demonstrated bladder\n        cancer."
            }
        }, 
        "enrollment": {
            "#text": "156", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706185", 
            "org_study_id": "111294"
        }, 
        "intervention": {
            "arm_group_label": "Cancer Group", 
            "description": "Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.", 
            "intervention_name": "Data acquisition and analysis", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Patients", 
            "Tumor antigens", 
            "Bladder cancer"
        ], 
        "lastchanged_date": "October 18, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "3000"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Analysis of the Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To determine the gene expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in pathologically demonstrated bladder cancer.", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706185"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}